| Toward defining the autoimmune microbiome for type 1 diabetes A Giongo, KA Gano, DB Crabb, N Mukherjee, LL Novelo, G Casella, ... The ISME journal 5 (1), 82-91, 2011 | 944 | 2011 |
| Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes CT Brown, AG Davis-Richardson, A Giongo, KA Gano, DB Crabb, ... PloS one 6 (10), e25792, 2011 | 863 | 2011 |
| PANGEA: pipeline for analysis of next generation amplicons A Giongo, DB Crabb, AG Davis-Richardson, D Chauliac, JM Mobberley, ... The ISME journal 4 (7), 852-861, 2010 | 137 | 2010 |
| Mortality and cardiovascular disease among older live kidney donors PP Reese, RD Bloom, HI Feldman, P Rosenbaum, W Wang, P Saynisch, ... American Journal of Transplantation 14 (8), 1853-1861, 2014 | 97 | 2014 |
| Template matching for auditing hospital cost and quality JH Silber, PR Rosenbaum, RN Ross, JM Ludwig, W Wang, BA Niknam, ... Health services research 49 (5), 1446-1474, 2014 | 76 | 2014 |
| Improving Medicare's hospital compare mortality model JH Silber, VA Satopää, N Mukherjee, V Rockova, W Wang, AS Hill, ... Health services research 51, 1229-1247, 2016 | 32 | 2016 |
| Bayesian Learning of Dynamic Multilayer Networks D Durante, N Mukherjee, RC Steorts JMLR 18 (43), 1−29, 2017 | 22 | 2017 |
| An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma A Younes, G Salles, RG Bociek, G Martinelli, D Caballero, EG Barca, ... Blood 124 (21), 1718, 2014 | 16 | 2014 |
| Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET). R Salazar, C Verslype, E Baudin, SK Libutti, JC Yao, R Buzzoni, ... Journal of Clinical Oncology 33 (15_suppl), 4102-4102, 2015 | 15 | 2015 |
| An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular … A Younes, G Salles, G Martinelli, RG Bociek, DC Barrigon, EG Barca, ... Blood 126 (23), 1493, 2015 | 10 | 2015 |
| Convergence analysis of some multivariate Markov chains using stochastic monotonicity K Khare, N Mukherjee | 10 | 2013 |
| Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy R Popovic, F Dunbar, C Lu, K Robinson, D Quarless, SE Warder, ... American Journal of Hematology 97 (2), E47, 2022 | 7 | 2022 |
| S146: venetoclax in patients with chronic lymphocytic leukemia with 17P deletion: 6-year follow-up and genomic analyses in a pivotal phase 2 trial S Stilgenbauer, E Tausch, AW Roberts, MS Davids, B Eichhorst, M Hallek, ... HemaSphere 6, 47-48, 2022 | 4 | 2022 |
| Bayesian learning of dynamic multilayer networks D Durante, N Mukherjee, RC Steorts arXiv preprint arXiv:1608.02209, 2016 | 3 | 2016 |
| CBEZ235Z2401: Randomized phase II study of BEZ235 or everolimus (EVE) in patients with advanced pancreatic neuroendocrine tumors (pNET) S Libutti, R Garcia-Carbonero, EM Wolin, A Custodio, JC Yao, ... Neuroendocrinology 102 (1-2), 131-131, 2015 | 3 | 2015 |
| Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del (17p) chronic lymphocytic leukemia S Stilgenbauer, E Tausch, AW Roberts, MS Davids, B Eichhorst, M Hallek, ... Blood Advances, 2024 | | 2024 |
| Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study M Herling, C Dearden, F Zaja, D El-Sharkawi, W Ding, M Bellido, A Khot, ... Blood Advances, 2024 | | 2024 |
| MO50-5 Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma K Izutsu, H Goto, M Kizaki, M Yamaguchi, N Fukuhara, K Kato, T Saito, ... Annals of Oncology 34, S1428, 2023 | | 2023 |
| Algorithms for improving efficiency of discrete Markov chains N Mukherjee, G Casella, K Khare Indian Journal of Pure and Applied Mathematics 48 (4), 495-511, 2017 | | 2017 |
| The Autoimmune Metagenome for Type 1 Diabetes Reveals Differences in the Metabolic Potential of an Aberrant Gut Micro biota CT Brown, A Giongo, AG Davis-Richardson, KA Gano, DB Crabb, ... DIABETES 60, A3-A3, 2011 | | 2011 |
